Physician profile
Keith Henry
NPI 1770017543
$5,139.38
in general payments reported to CMS, 2019-2025
24 companies · $860 in 2025
The $860 reported for 2025 was more than what 94% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $302 · 2021: $944 · 2022: $1,052 · 2023: $916 · 2024: $1,066 · 2025: $860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,842.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,842.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,000.17 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $644.27 | 2020-2025 | Zerbaxa, Dificid, Verquvo |
| Novartis Pharmaceuticals Corporation | $495.72 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $493.64 | 2021-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Abbvie INC. | $455.08 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $367.22 | 2020-2024 | Farxiga, Lokelma |
| Janssen Pharmaceuticals, INC | $349.20 | 2020-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $271.46 | 2020-2025 | Xifaxan |
| Gilead Sciences, INC. | $229.51 | 2021-2024 | Veklury |
| E.R. Squibb & Sons, L.L.C. | $151.46 | 2021-2024 | Eliquis, Camzyos |
| Alexion Pharmaceuticals, INC. | $129.56 | 2021-2025 | Ultomiris |
| Sk Life Science, INC. | $103.37 | 2025 | |
| Boston Scientific Corporation | $71.58 | 2020-2022 | |
| Paratek Pharmaceuticals, INC. | $71.11 | 2022 | |
| Novo Nordisk INC | $55.08 | 2023-2024 | Rybelsus, Ozempic |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $49.50 | 2021-2023 | |
| Smith+Nephew, INC. | $38.77 | 2025 | Collagenase Santyl |
| Cvrx, INC. | $29.40 | 2024 | Barostim Neo System |
| Electromed, INC. | $28.78 | 2023 | Smartvest |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.07 | 2025 | Lifevest |
| Abbott Laboratories | $23.47 | 2024 | Mitraclip |
| Cmp Pharma, INC. | $22.15 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.20 | 2024 | |
| Melinta Therapeutics, LLC | $13.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Henry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.